Detail akcie Cumberland Ph online

Business Summary: Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Cumberland Pharmaceuticals, Inc. revenues increased 23% to $22.6M. Net income totaled $516K vs. loss of $3M. Revenues reflect Other segment increase from $489K to $3.6M, Sancuso segment increase of 34% to $5.4M. Net Income reflects Amortization decrease of 9% to $2M (expense), Interest Income increase of 60% to $253K (income).